Pharmaron developed a COVID-19 Risk Reduction Plan to ensure the safety of study participants and staff. Study participants are tested for the novel coronavirus and are given masks to wear. Our staff is tested for the novel coronavirus and required to wear full PPE.
Pharmaron’s vision is to provide clinical development services to our global customers in support of international regulatory approval, in particular, in the U.S and China. We have aligned our capabilities and services to meet the drug development industry’s expectation for more thorough evaluation of investigational products in the earlier phases of clinical development.
Our Maryland-based clinical research center and bioanalytical laboratory has a team of highly experienced principal investigators with expertise in clinical pharmacology, and supporting staff that have successfully conducted over 250 early phase clinical trials in the U.S. The center specializes in integrated FIH, 14C human ADME, TQT/cardiac safety, ethnobridging, vaccine development/challenge and patient recruitment.
Learn More: Download Clinical Development Services Overview